GlassScriptPhysician profile
Edgar Castillo Dandreis
NPI 1396974135
$7,133.07
in general payments reported to CMS, 2019-2025
51 companies · $3,327 in 2025
The $3,327 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.66 · 2020: $12.45 · 2021: $278 · 2022: $811 · 2023: $1,264 · 2024: $1,416 · 2025: $3,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,806 · Consulting Fee: $1,080 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,805.83 |
| Consulting Fee | $1,080.00 |
| Education | $120.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,289.73 | 2023-2025 | Rybrevant, Erleada, Carvykti |
| Astrazeneca Pharmaceuticals LP | $588.44 | 2022-2025 | Tagrisso, Enhertu, Lynparza |
| Pfizer INC. | $388.13 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $369.62 | 2022-2025 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $357.81 | 2022-2025 | Opdivo, Krazati, Opdualag |
| Genzyme Corporation | $302.30 | 2021-2025 | |
| Eisai INC. | $274.28 | 2021-2025 | |
| Genentech USA, INC. | $246.37 | 2021-2025 | Tecentriq, Itovebi, Phesgo |
| Novartis Pharmaceuticals Corporation | $223.17 | 2021-2025 | |
| Astellas Pharma US INC | $212.63 | 2021-2025 | Xospata, Vyloy, Padcev |
| Emd Serono, INC. | $194.00 | 2022-2025 | Bavencio |
| Exelixis INC. | $159.82 | 2021-2025 | Cabometyx |
| Incyte Corporation | $145.85 | 2024-2025 | Jakafi, Pemazyre, Monjuvi |
| Array Biopharma INC | $131.75 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Galvanize Therapeutics, INC | $130.14 | 2025 | Aliya System |
Show all 50 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Castillo Dandreis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.